ACRS – aclaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4/8
08:30 am
acrs
Low
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
3/31
10:20 am
acrs
Low
Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush. They now have a $8.00 price target on the stock.
3/27
10:10 am
acrs
Low
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
3/20
11:00 am
acrs
Low
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
3/19
08:22 am
acrs
Medium
Aclaris Therapeutics (ACRS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.
2/26/2026
06:58 am
ACRS
-7.8%
MISS
11/6/2025
06:59 am
ACRS
0.4%
BEAT
8/7/2025
06:59 am
ACRS
1.3%
IN-LINE
5/8/2025
06:50 am
ACRS
7.4%
BEAT
3/31
10:20 am
Reiterates
Outperform
Outperform
Wedbush
Low
2.3%
3/31
10:20 am
Reiterates
Outperform
Outperform
Wedbush
Low
2.3%
3/31
09:59 am
Reiterates
Outperform
Outperform
Wedbush
Low
2.7%
3/31
09:59 am
Reiterates
Outperform
Outperform
Wedbush
Low
2.7%
3/19
08:22 am
Reiterates
Buy
Buy
HC Wainwright
Medium
5.6%
4/7
06:00 pm
acrs
Medium
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
3/26
03:06 pm
acrs
Low
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: VANGUARD GROUP INC
3/17
04:17 pm
acrs
Medium
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: Deep Track Capital, LP
3/11
04:31 pm
acrs
Medium
Form 8-K Aclaris Therapeutics, For: Mar 10
3/10
06:03 am
acrs
Medium
Form 8-K Aclaris Therapeutics, For: Mar 09
Show more
Top News Gainers
9/16 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) 63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
Top News Decliners
6/26 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints -52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3